Pfizer says its new COVID-19 pill reduces 89% of serious illnesses

Nothing lasts forever. Including the coronavirus.

Pfizer says its new COVID-19 pill could reduce recipients’ risk of hospitalization or death by a staggering 89 percent, according to press release from the company.

This could mean the end of the COVID-19 pandemic.

Pfizer’s new COVID-19 pill works best with ritonavir

The medicine taken by mouth from Pfizer is called Paxlovid and is very similar the new pill from Merck which Britain approved on Thursday. Pfizer claims that its new pill has shown positive results when given to patients within the first five days after the onset of symptoms of COVID-19, according to the report. The strength of the recent trial motivated the pharmaceutical company to stop the process of enrolling more people in subsequent clinical trials and instead send its results directly to the US Food and Drug Administration (FDA), hoping to gain emergency use. permission. “These data suggest that our oral antiviral candidate, if approved or authorized by regulators, has the potential to save patients’ lives, reduce the severity of COVID-19 infections and eliminate up to nine out of ten hospitalizations,” said Albert Burla. . , CEO of Pfizer, in the report.

Antiviral drugs from both Merck and Pfizer work by interfering with the coronavirus’ ability to reproduce itself. Pfizer also added that ritonavir, a drug used in HIV / AIDS treatment procedures, could improve the effectiveness of the pill. Ritonavir supports the new Pfizer pill by helping protease inhibitors – including such as the new COVID-19 pill – stay in human bodies longer, which in turn makes them much more capable of fighting the virus deadly. U.S. and UK officials say COVID-19 pills could fundamentally transform the ongoing battle against the global pandemic, possibly even put it down. And they can be completely administered from the comfort of your own home. In particular, the Regeneron antibody cocktail has become a crucial feature of medical professionals’ efforts to prevent terrible ends for those infected with the virus, but this treatment requires either several injections or an intravenous infusion.

Not so for the new Pfizer pill.

Pfizer will offer a “multi-level pricing approach” in different countries

The company also said its new drug could be prescribed to fight and reduce the severity of patients suffering from COVID-19, in addition to reducing the likelihood of developing an infection after exposure to the virus. “It has demonstrated potent antiviral activity in vitro against circulating variants of concern, as well as other known coronaviruses, suggesting its potential as a therapeutic agent for many types of coronavirus infections,” the company said in a statement. “All of us at Pfizer are incredibly proud of our scientists who designed and developed the molecule, working with the utmost urgency, to help reduce the impact of this devastating disease on patients and their communities,” said the chief research officer and president of world research, development and medicine Mikael Dolsten from Pfizer.

Most importantly, Pfizer strives to offer “equal access” to its new Paxlovid pill to everyone, with a focus on delivering the pill as quickly as possible at an affordable price. “If our candidate is successful, during the pandemic, Pfizer will offer our research oral antiviral therapy through a pricing approach based on each country’s income level to promote equity,” the press release said. This is great news that signals the upcoming horizon of post-coronavirus world.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button